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A Breast Clinical Studies Group seeks to support the 
initiation, development, recruitment to and reporting of 
clinical studies and randomised controlled trials. In the 
United Kingdom, the National Cancer Research Institute 
(NCRI) Breast Cancer Clinical Studies Group serves 
these functions (Figure 1).
Trials utilising drugs, radiation and/or surgery are 
usually conceptualised, discussed and developed or 
adopted from other (international) trials organisations 
via the three subgroups: the UK breast intergroup for 
adjuvant and perioperative studies (usually the develop-
ment of later phase trials), the advanced disease subgroup 
or the translational and imaging subgroup. Individuals 
with good ideas, sometimes with links to industry, will 
engage with Clinical Trials Units and other external 
organisations. In addition, there is an adoption panel for 
early phase drug trials led by Industry.
Industry-trialist interactions include identifying 
individuals with an interest in the pathway/compound, 
early discussion with interested parties and an approach 
to the Breast Clinical Studies Group. Th  e challenges of 
such interactions include the time taken to go through 
both the company and legislation required processes, the 
need for biological samples (which may be particularly 
problematic for metastatic breast cancer), how to reach 
‘new’ investigators and how to compete with processes in 
the US and elsewhere.
Th  ere is a continuing need for prompt and open 
communi  cation between all parties, and adherence to the 
formal processes with properly recorded discussions and 
decisions. Work behind the scenes may signiﬁ  cantly 
speed the process along, but occasionally can be dis-
ruptive. Additional considerations include the potential 
for competing trials in the UK (for example HER2 
therapies in advanced disease) and particularly the 
delivery of accrual to trials and where trials fail to achieve 
recruitment targets, termination of the trial.
Th  e success of the Breast Clinical Studies Group is 
reﬂ   ected in the 16,108 patients entered into trials/
observational studies in 2009/2010, of whom 4,121 
patients were entered into randomised controlled trials. 
Th   ese totals represent 30 to 45% of UK cancer patients in 
trials. Perhaps more importantly, through plenary and 
poster presentations at international cancer meetings 
and through peer reviewer publications, signiﬁ  cant 
changes in clinical practice have been achieved.
While the processes of trial development and imple-
men  tation may be complex, but can successfully involve 
Industry, the independent NCRI Breast Clinical Studies 
Group seeks to improve the prevention, diag  nosis, 
treatment and prognosis of patients with breast cancer.
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Figure 1. Structure and interaction of the National Cancer 
Research Institute (NCRI) Breast Clinical Studies Group. BIDD, 
Biomarkers and Imaging Discovery and Development Committee; 
CTACC, Clinical Trials Advisory and Awards Committee; EORTC, 
European Organisation for Research and Treatment of Cancer; HTA, 
Health Technology Assessment; IBCSG, International Breast Cancer 
Study Group; ITAC, Industry Trials Adoption Committee.
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